Computational modelling allows insights into cell membrane fusion

Researchers from France, the UK and Austria have modelled the SNARE protein complex that acts as a catalyst in the fusion of two membranes, using the processing power of the Distributed European Infrastructure for Supercomputing Applications (DEISA). They hope to open up new opportunities for pharmaceutical development.

"Basic research is essential, since there are several aspects concerning the functioning of proteins and cell membranes that are not yet fully understood. A better understanding of these mechanisms will facilitate, for example, the development of new pharmaceutical agents," explains Dr Marc Baaden, researcher at the Laboratory of Theoretical Biochemistry in Paris. "By examining a phenomenon at the atomic level, we can gain insight into the behaviour of cell membranes and proteins in general and on a larger scale."

Many diseases are associated with functional disorders of the cell membranes. In the case studied by Dr Baaden and his colleagues, the cell membranes either do not fuse at all or fuse too heavily. The SNARE protein complex is responsible for this fusion. Disturbed functioning of the SNARE proteins may result in adult-onset diabetes, for example. Hence, understanding the SNARE function may facilitate development of new therapeutic treatments. Apart from medical science, the cosmetics industry and nanotechnology will benefit from a better understanding of protein functioning.

"Knowledge of the functioning of cell membranes will open up opportunities in the field of nanotechnology as well. In technical terms, the proteins we study are clever machines that perform their intended tasks excellently, that is, to fuse two lipid membranes firmly together," Dr Baaden points out.

While researchers frequently have to resort to pen and paper when describing events at molecule level - a technique that Dr Baaden dubs 'cartoon biology' and criticises for being easily misleading - the scientists involved in this study had been granted access to the DEISA network in the framework of the DEISA Extreme Computing Initiative (DECI), enabling them to develop am exceptionally complex model.

"Computational molecular modelling, or simulation, takes the physical properties into account in a more realistic manner," Dr Baaden states. "A good molecular model enables us to examine the smallest details of the system in a controlled fashion and under the desired circumstances. We can also easily change any of the properties of the model to test different hypotheses." As a result, simulation facilitates the examination of dynamic events.

"Traditionally, computational modelling has been applied to simulate a single membrane - this is already a very challenging task. We, however, simulated two lipid membranes held together by a protein complex, so our challenge was even greater," Dr. Baaden says.

For him, in the future, computational modelling methods will have to combine highly accurate atomic level modelling with coarse-grained models simulating a more extensive event. In addition, "communication between the simulations on various levels is important. This will allow us to simulate a detail of particular significance more accurately, and larger entities by means of a coarse-grained model," Dr Baaden concludes.

For further information, please visit:

  • http://www.deisa.org
  • http://www.baaden.ibpc.fr

    Copyright ©European Communities, 2007
    Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Ancient viral DNA in human genome guards against i…

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new res...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...